Shorter HER2-targeted Therapy for Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests if a shorter treatment period is effective for early-stage, HER2-positive breast cancer patients who have responded well to initial treatment. The aim is to reduce side effects and costs while maintaining treatment effectiveness. For many years, a longer treatment period has been the standard for these patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is trastuzumab safe for humans?
Trastuzumab, also known as Herceptin, is generally safe for humans, but it can cause some side effects. The most common serious side effect is heart-related issues, especially in patients who have had certain other cancer treatments. Other side effects can include mild reactions when the drug is first given, but these are usually not severe.12345
How does the drug trastuzumab differ from other treatments for HER2-positive breast cancer?
Trastuzumab is unique because it specifically targets the HER2 protein on cancer cells, which is overexpressed in some aggressive breast cancers. This targeted approach can improve the effectiveness of chemotherapy and has been shown to significantly reduce relapse rates in HER2-positive breast cancer patients.678910
What data supports the effectiveness of the drug Trastuzumab for breast cancer?
Research shows that Trastuzumab, when used alone or with chemotherapy, helps shrink tumors and improve survival in patients with HER2-positive breast cancer. It has been effective in both early and advanced stages of the disease, making it a successful targeted therapy for this type of cancer.67111213
Who Is on the Research Team?
Sharon McGee
Principal Investigator
Ottawa Hospital Research Institute
Are You a Good Fit for This Trial?
This trial is for people with early-stage HER2-positive breast cancer who've had a complete response to initial chemo and HER2 therapy. They should not have any remaining invasive cancer after pre-surgery treatment, be able to consent in English or French, and haven't yet received 6 months of HER2 therapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 6 months of HER2-targeted therapy after achieving a pathological complete response to neoadjuvant systemic therapy
Follow-up
Participants are monitored for disease-free survival, overall survival, and cardiac events
What Are the Treatments Tested in This Trial?
Interventions
- Trastuzumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ottawa Hospital Research Institute
Lead Sponsor